TX1-85-1
CAS No. 1603845-32-4
TX1-85-1 ( —— )
Catalog No. M23702 CAS No. 1603845-32-4
TX1-85-1 induces partial degradation of Her3 protein and attenuates Her3-dependent signaling.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 140 | In Stock |
|
10MG | 250 | In Stock |
|
25MG | 401 | In Stock |
|
50MG | 591 | In Stock |
|
100MG | Get Quote | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTX1-85-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionTX1-85-1 induces partial degradation of Her3 protein and attenuates Her3-dependent signaling.
-
DescriptionTX1-85-1 induces partial degradation of Her3 protein and attenuates Her3-dependent signaling. TX1-85-1 is an irreversible Her3 inhibitor (IC50: 23 nM). TX1-85-1 is also the first selective Her3 ligand, which forms a covalent bond with Cys721 located in the ATP-binding site of Her3.
-
Synonyms——
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorErbB3
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1603845-32-4
-
Formula Weight580.7
-
Molecular FormulaC32H36N8O3
-
Purity>98% (HPLC)
-
SolubilityDMSO:3.85 mg/mL (6.63 mM; Need ultrasonic)
-
SMILESCC(N1CCN(C2CCC(N3N=C(C4=CC(NC(C=C)=O)=C(OC5=CC=CC=C5)C=C4)C6=C3N=CN=C6N)CC2)CC1)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Xie T, et al. Pharmacological targeting of the pseudokinase Her3. Nat Chem Biol. 2014 Dec;10(12):1006-12.
molnova catalog
related products
-
BMS-690514
A potent pan HER/VEGFR inhibitor with IC50 of 5/20/60/50 nM for EGFR/HER2/ERBB4/VEGFR2 respectively.
-
Olmutinib
Olmutinib is a Novel Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorOlmutinib at 3 μM significantly reversed drug resistance mediated by ABCG2, but not by ABCB1 and ABCC1, by antagonizing the drug efflux function in ABCG2-overexpressing cells.?
-
(Rac)-JBJ-04-125-02
JBJ-04-125-02 is effective as a single agent in both in vitro and in vivo models of EGFR-mutant lung cancer.